CDC25A

Across TCGA pan-cancer cohorts, CDC25A RNA differs between tumor and matched normal tissue in 16 of 18 cancer types tested, making tumor–normal expression one of CDC25A’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where CDC25A RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CDC25A is over-expressed in tumor, although a few such as THCA and KIRC show the opposite, repressed pattern.

BLCA, LUAD, and COAD are the cancer types where CDC25A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CDC25A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	III,IV	+2.821	<.001	12	view →
LUAD	Male	III,IV	+2.188	<.001	11	view →
COAD	Female	II,III,IV	+1.467	<.001	11	view →
THCA	Male	All	−0.760	<.001	10	view →
STAD	Female	All	+1.955	<.001	9	view →
LIHC	Female	II,III,IV	+1.353	<.001	9	view →
UCEC	All	III,IV	+2.990	<.001	8	view →
LUSC	Male	III,IV	+2.725	<.001	8	view →
HNSC	Male	All	+1.266	<.001	8	view →
BRCA	All	III,IV	+1.391	<.001	6	view →
KIRP	All	III,IV	+0.689	.001	6	view →
KIRC	Male	All	−0.270	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 16 lineages.

CDC25A–BLCA

Open the BLCA breakdown →